Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:BNTX NASDAQ:INSM NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsBNTXBioNTech$93.93-3.7%$92.64$79.52▼$124.00$24.67B1.32956,111 shs784,899 shsINSMInsmed$111.54-0.1%$108.77$90.39▼$212.75$24.19B0.784.60 million shs2.23 million shsROIVRoivant Sciences$35.39+0.7%$30.38$10.70▼$35.90$25.27B1.115.82 million shs5.98 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%0.00%+0.24%+70.99%BNTXBioNTech-3.70%-0.35%+6.64%+4.81%-14.33%INSMInsmed-0.05%+6.49%+18.38%-31.58%+13.24%ROIVRoivant Sciences+0.74%+1.90%+23.83%+27.53%+226.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsBNTXBioNTech$93.93-3.7%$92.64$79.52▼$124.00$24.67B1.32956,111 shs784,899 shsINSMInsmed$111.54-0.1%$108.77$90.39▼$212.75$24.19B0.784.60 million shs2.23 million shsROIVRoivant Sciences$35.39+0.7%$30.38$10.70▼$35.90$25.27B1.115.82 million shs5.98 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%0.00%+0.24%+70.99%BNTXBioNTech-3.70%-0.35%+6.64%+4.81%-14.33%INSMInsmed-0.05%+6.49%+18.38%-31.58%+13.24%ROIVRoivant Sciences+0.74%+1.90%+23.83%+27.53%+226.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.11Hold$111.87-2.78% DownsideBNTXBioNTech 2.74Moderate Buy$129.5637.94% UpsideINSMInsmed 2.96Moderate Buy$211.8689.94% UpsideROIVRoivant Sciences 2.75Moderate Buy$33.59-5.08% DownsideCurrent Analyst Ratings BreakdownLatest ACLX, ROIV, BNTX, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026INSMInsmed MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$192.006/10/2026INSMInsmed Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/8/2026INSMInsmed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026INSMInsmed JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$180.00 ➝ $179.006/5/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/5/2026INSMInsmed Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$205.00 ➝ $195.006/1/2026BNTXBioNTech Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026BNTXBioNTech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$117.00 ➝ $135.005/26/2026ROIVRoivant Sciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $36.005/22/2026ROIVRoivant Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/21/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$96.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$22.29M301.95N/AN/A$6.96 per share16.53BNTXBioNTech$3.25B7.32$1.29 per share73.06$96.59 per share0.97INSMInsmed$606.42M39.87N/AN/A$3.46 per share32.24ROIVRoivant Sciences$8.26M3,081.71N/AN/A$7.35 per share4.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$228.93M-$4.07N/AN/AN/A-1,027.26%-55.42%-36.24%N/ABNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/4/2026 (Estimated)INSMInsmed-$1.28B-$5.75N/A137.70N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)ROIVRoivant Sciences-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)Latest ACLX, ROIV, BNTX, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026ROIVRoivant Sciences-$0.2893$0.28+$0.5693$0.28$3.41 million$2.52 million5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/ABNTXBioNTechN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.444.44BNTXBioNTech0.018.808.74INSMInsmed0.804.474.10ROIVRoivant SciencesN/A18.3718.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%BNTXBioNTech15.52%INSMInsmedN/AROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%BNTXBioNTech19.20%INSMInsmed2.10%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8058.48 million53.60 millionOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableINSMInsmed1,664216.75 million212.20 millionOptionableROIVRoivant Sciences860719.27 million641.59 millionOptionableACLX, ROIV, BNTX, and INSM HeadlinesRecent News About These CompaniesInsider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells $436,766.40 in StockJuly 3, 2026 | americanbankingnews.comMelissa Epperly Sells 17,750 Shares of Roivant Sciences (NASDAQ:ROIV) StockJuly 3, 2026 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 17,750 SharesJuly 2, 2026 | insidertrades.comDaniel Allen Gold Sells 12,380 Shares of Roivant Sciences (NASDAQ:ROIV) StockJuly 1, 2026 | insidertrades.comRoivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 800,000 Shares of StockJuly 1, 2026 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 625,783 Shares of StockJuly 1, 2026 | americanbankingnews.comRoivant Sciences Ltd. $ROIV Shares Sold by Capricorn Fund Managers LtdJuly 1, 2026 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Director Sells 625,783 Shares of StockJune 30, 2026 | marketbeat.comDaniel Allen Gold Sells 800,000 Shares of Roivant Sciences (NASDAQ:ROIV) StockJune 30, 2026 | marketbeat.comPictet Asset Management Holding SA Raises Holdings in Roivant Sciences Ltd. $ROIVJune 30, 2026 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Sets New 52-Week High - What's Next?June 29, 2026 | marketbeat.comPeak Financial Advisors LLC Takes $2.93 Million Position in Roivant Sciences Ltd. $ROIVJune 29, 2026 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 29, 2026 | marketbeat.com130,700 Shares in Roivant Sciences Ltd. $ROIV Purchased by Louisiana State Employees Retirement SystemJune 28, 2026 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 SharesJune 26, 2026 | marketbeat.comRoivant Sciences Ltd. $ROIV Stake Reduced by Penn Davis Mcfarland Inc.June 26, 2026 | marketbeat.comSG Americas Securities LLC Acquires 617,629 Shares of Roivant Sciences Ltd. $ROIVJune 26, 2026 | marketbeat.comAssenagon Asset Management S.A. Has $196.02 Million Position in Roivant Sciences Ltd. $ROIVJune 25, 2026 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Hits New 12-Month High - Here's WhyJune 23, 2026 | marketbeat.com170,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Creek Drive Management Group LLCJune 21, 2026 | marketbeat.comDorsey Wright & Associates Invests $8.16 Million in Roivant Sciences Ltd. $ROIVJune 19, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACLX, ROIV, BNTX, and INSM Company DescriptionsArcellx NASDAQ:ACLXArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.BioNTech NASDAQ:BNTX$93.93 -3.61 (-3.70%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$93.06 -0.87 (-0.93%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$111.54 -0.06 (-0.05%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$112.95 +1.41 (+1.26%) As of 05:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Roivant Sciences NASDAQ:ROIV$35.39 +0.26 (+0.74%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$35.50 +0.11 (+0.31%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
